Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRADE study of glycodeoxycholic acid in healthy men and men with type 2 diabetes mellitus
NL-OMON55800Phase 1Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glycodeoxycholic acid and ezetimibe in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety of long-term glycodeoxycholic acid administration, Postprandial GLP-1 secretion and 3 more. Started Jun 2018; status: active, not recruiting.
02
Drugs
glycodeoxycholic acidezetimibe
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55800.